PDF(Pubmed)
Abstract：
UNASSIGNED: Pharmacogenomics research is currently revolutionizing treatment optimization by discovering molecular markers. Medicines are the cornerstone of treatment for both acute and chronic diseases. Pharmacogenomics associated treatment response varies from 20% to 95%, resulting in from lack of efficacy to serious toxicity. Pharmacogenomics has emerged as a useful tool for therapy optimization and plays a bigger role in clinical care going forward. However, in Africa, in particular in Ethiopia, such studies are scanty and not generalizing. Therefore, the objective of this review was to outline such studies, generating comprehensive evidence and identify studied variants\' association with treatment responses in Ethiopian patients.
UNASSIGNED: The Joanna Briggs Institute\'s updated 2020 methodological guidelines for conducting and guidance for scoping reviews were used. We meticulously adhered to the systemic review reporting items checklist and scoping review meta-analyses extension.
UNASSIGNED: Two hundred twenty-nine possibly relevant studies were searched. These include: 64, 54, 21, 48 and 42 from PubMed, Scopus, Google Scholar, EMBASE, and manual search, respectively. Seventy-seven duplicate studies were removed. Thirty-nine papers were rejected with justification, whereas 58 studies were qualified for full-text screening. Finally 19 studies were examined. The primary pharmacogene that was found to have a significant influence on the pharmacokinetics of efavirenz was CYP2B6. Drug-induced liver injury has frequently identified toxicity among studied medications.
UNASSIGNED: Pharmacogenomics studies in Ethiopian populations are less abundant. The studies conducted focused on infectious diseases, specifically on HAART commonly efavirenz and backbone first-line anti-tuberculosis drugs. There is a high need for further pharmacogenomics research to verify the discrepancies among the studies and for guiding precision medicine. Systematic review and meta-analysis are also recommended for pooled effects of different parameters in pharmacogenomics studies.
UNASSIGNED: The Joanna Briggs Institute\'s updated 2020 methodological guidelines for conducting and guidance for scoping reviews were used. We meticulously adhered to the systemic review reporting items checklist and scoping review meta-analyses extension.
UNASSIGNED: Two hundred twenty-nine possibly relevant studies were searched. These include: 64, 54, 21, 48 and 42 from PubMed, Scopus, Google Scholar, EMBASE, and manual search, respectively. Seventy-seven duplicate studies were removed. Thirty-nine papers were rejected with justification, whereas 58 studies were qualified for full-text screening. Finally 19 studies were examined. The primary pharmacogene that was found to have a significant influence on the pharmacokinetics of efavirenz was CYP2B6. Drug-induced liver injury has frequently identified toxicity among studied medications.
UNASSIGNED: Pharmacogenomics studies in Ethiopian populations are less abundant. The studies conducted focused on infectious diseases, specifically on HAART commonly efavirenz and backbone first-line anti-tuberculosis drugs. There is a high need for further pharmacogenomics research to verify the discrepancies among the studies and for guiding precision medicine. Systematic review and meta-analysis are also recommended for pooled effects of different parameters in pharmacogenomics studies.
摘要：
■药物基因组学研究目前正在通过发现分子标记来彻底改变治疗优化。药物是治疗急性和慢性疾病的基石。药物基因组学相关治疗反应从20%到95%不等，导致从缺乏疗效到严重的毒性。药物基因组学已成为治疗优化的有用工具，并在未来的临床护理中发挥更大的作用。然而,在非洲,特别是在埃塞俄比亚，这样的研究很少，不能一概而论。因此,这次审查的目的是概述这些研究，生成全面的证据，并确定研究的变异与埃塞俄比亚患者治疗反应的关联。
■使用了乔安娜·布里格斯研究所更新的2020年方法指南，用于进行范围审查和指导。我们一丝不苟地遵守系统审查报告项目清单和范围审查荟萃分析扩展。
■检索了二百二十九个可能相关的研究。其中包括：PubMed的64、54、21、48和42，Scopus,谷歌学者，EMBASE,和手动搜索，分别。删除了77项重复研究。三十九篇论文被拒绝，理由是合理的，而58项研究符合全文筛选条件.最后对19项研究进行了研究。发现对依非韦仑的药代动力学具有显着影响的主要药源是CYP2B6。药物诱导的肝损伤在所研究的药物中经常发现毒性。
■埃塞俄比亚人群的药物基因组学研究较少。进行的研究集中在传染病上，特别是对HAART通常是依非韦仑和骨干一线抗结核药物。迫切需要进一步的药物基因组学研究以验证研究之间的差异并指导精准医学。还建议对药物基因组学研究中不同参数的综合影响进行系统评价和荟萃分析。
■使用了乔安娜·布里格斯研究所更新的2020年方法指南，用于进行范围审查和指导。我们一丝不苟地遵守系统审查报告项目清单和范围审查荟萃分析扩展。
■检索了二百二十九个可能相关的研究。其中包括：PubMed的64、54、21、48和42，Scopus,谷歌学者，EMBASE,和手动搜索，分别。删除了77项重复研究。三十九篇论文被拒绝，理由是合理的，而58项研究符合全文筛选条件.最后对19项研究进行了研究。发现对依非韦仑的药代动力学具有显着影响的主要药源是CYP2B6。药物诱导的肝损伤在所研究的药物中经常发现毒性。
■埃塞俄比亚人群的药物基因组学研究较少。进行的研究集中在传染病上，特别是对HAART通常是依非韦仑和骨干一线抗结核药物。迫切需要进一步的药物基因组学研究以验证研究之间的差异并指导精准医学。还建议对药物基因组学研究中不同参数的综合影响进行系统评价和荟萃分析。
